{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:36Z","timestamp":1787028636045,"version":"build-2736575974"},"reference-count":80,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Leo Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against interleukin-17RA that has been approved for the treatment of moderate-to-severe psoriasis in Europe. We developed a Delphi consensus document focused on brodalumab for the treatment of moderate-to-severe psoriasis. Based on published literature and their clinical experience a steering committee drafted 17 statements covering 7 domains specific to the treatment of moderate-to-severe psoriasis with brodalumab. A panel of 32 Italian dermatologists indicated their level of agreement using a 5-point Likert scale (from 1 = \u201cstrongly disagree\u201d to 5 = \u201cstrongly agree\u201d) using an online modified Delphi method. After the first round of voting (32 participants), positive consensus was reached for 15\/17 (88.2%) of the proposed statements. Following a face-to-face virtual meeting, the steering committee decided that 5 statements would form \u201cmain principles\u201d and 10 statements formed the final list. After a second round of voting, consensus was reached in 4\/5 (80%) of the main principles and 8\/10 (80%) for consensus statements. The final list of 5 main principles and 10 consensus statements identify key indications specific to the use of brodalumab in the treatment of moderate-to-severe psoriasis in Italy. These statements aid dermatologists in the management of patients with moderate-to-severe psoriasis.<\/jats:p>","DOI":"10.3390\/jcm12103545","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:35:50Z","timestamp":1684395350000},"page":"3545","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7249-2556","authenticated-orcid":false,"given":"Maria Concetta","family":"Fargnoli","sequence":"first","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"},{"name":"Dermatology Unit, Ospedale San Salvatore, 67100 L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[{"name":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola Malpighi, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Azienda Ospedaliera Universitaria \u201cPoliclinico Tor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Medical Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical, Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Section of Dermatology and Venereology, Department of Medicine, University of Verona, 37129 Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Micali","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Offidani","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Dermatology Unit, Polytechnic Marche University, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellacani","sequence":"additional","affiliation":[{"name":"Dermatology Clinic, Department of Clinical Internal, Anesthesiologic and Cardiovascular Sciences, Sapienza Medical School, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4478-5404","authenticated-orcid":false,"given":"Nevena","family":"Skroza","sequence":"additional","affiliation":[{"name":"Dermatology Unit \u201cD. Innocenzi\u201d, Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome-Polo Pontino, 04100 Latina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Giuseppa","family":"Angileri","sequence":"additional","affiliation":[{"name":"UOC Dermatologia, ARNAS Civico Di Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4381-6718","authenticated-orcid":false,"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, DissaL, Ospedale Policlinico San Martino-IRCCS, 16132 Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3740-0839","authenticated-orcid":false,"given":"Anna","family":"Campanati","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Sciences, Dermatology Clinic, Polytechnic Marche University, 60121 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Giovanni","family":"Carrera","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Internal Medicine, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Conti","sequence":"additional","affiliation":[{"name":"Dermatologic Unit, Department of Surgery, Infermi Hospital, AUSL Romagna, 47923 Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0898-0045","authenticated-orcid":false,"given":"Clara De","family":"Simone","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Di Lernia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Arcispedale S. Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzo","family":"Errichetti","sequence":"additional","affiliation":[{"name":"Institute of Dermatology, Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-5175","authenticated-orcid":false,"given":"Marco","family":"Galluzzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Dermatology Unit, Azienda Ospedaliera Universitaria \u201cPoliclinico Tor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-8779","authenticated-orcid":false,"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[{"name":"Clinica Dermatologica, Dipartimento delle Medicine Specialistiche AOU Policlinico di Modena, 41121 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Lembo","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Dentistry, \u201cScuola Medica Salernitana\u201d, University of Salerno, 84084 Fisciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, 70121 Bari, Italy"},{"name":"Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-2046","authenticated-orcid":false,"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical, Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Letizia","family":"Musumeci","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5997-2045","authenticated-orcid":false,"given":"Francesca","family":"Prignano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Giovanni","family":"Richetta","sequence":"additional","affiliation":[{"name":"Unit of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8301-9206","authenticated-orcid":false,"given":"Emanuele","family":"Trovato","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Medical, Surgical and Neurological Science, S. Maria alle Scotte Hospital, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Venturini","sequence":"additional","affiliation":[{"name":"Dermatology Department, University of Brescia, 25121 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli\u2013IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiacomo Calzavara","family":"Pinton","sequence":"additional","affiliation":[{"name":"Dermatology Department, University of Brescia, 25121 Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjd.16686","article-title":"The multidimensional burden of psoriasis","volume":"179","author":"Gisondi","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J. Eur. Acad. Derm. Venereol"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_4","first-page":"504","article-title":"The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives","volume":"9","author":"Feldman","year":"2016","journal-title":"Am. Health Drug Benefits"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gisondi, P., Del Giglio, M., and Girolomoni, G. (2017). Treatment Approaches to Moderate to Severe Psoriasis. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112427"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","article-title":"Manifestations and Management of Difficult-to-Treat Psoriasis","volume":"10","author":"Aldredge","year":"2018","journal-title":"J. Dermatol. Nurses\u2019 Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Derm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J. Am. Acad. Derm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000484520","article-title":"Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials","volume":"233","author":"Naik","year":"2017","journal-title":"Dermatology"},{"key":"ref_10","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital. J. Derm. Venerol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris\u2014Part 1: Treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","first-page":"469","article-title":"Tuscany consensus for the treatment of moderate-severe psoriasis: Update and focus on practical guidelines for place in therapy of anti-IL-17 and anti-IL-23 biologics","volume":"157","author":"Prignano","year":"2022","journal-title":"Ital. J. Dermatol. Venereol."},{"key":"ref_13","unstructured":"(2021, April 20). European Medicines Agency Kyntheum|European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kyntheum."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1038\/jid.2012.163","article-title":"Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: Results from a phase I, randomized, placebo-controlled trial","volume":"132","author":"Papp","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","article-title":"Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody","volume":"192","author":"Russell","year":"2014","journal-title":"J. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J. Investig. Derm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an Anti\u2013Interleukin-17\u2013Receptor Antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"138","article-title":"Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis","volume":"19","author":"Green","year":"2020","journal-title":"J. Drugs Derm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CCID.S211938","article-title":"Brodalumab for the treatment of moderate-to-severe psoriasis: Case series and literature review","volume":"12","author":"Pinter","year":"2019","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/bjd.17318","article-title":"Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: Subgroup analysis of two randomized phase III trials","volume":"180","author":"Langley","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","article-title":"Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed","volume":"81","author":"Kimmel","year":"2019","journal-title":"J. Am. Acad. Derm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br. J. Derm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09546634.2018.1427205","article-title":"The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis","volume":"29","author":"Sawyer","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaad.2017.03.026","article-title":"Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Derm."},{"key":"ref_27","first-page":"419","article-title":"Brodalumab: 4-Year US Pharmacovigilance Report","volume":"22","author":"Lebwohl","year":"2023","journal-title":"J. Drugs Derm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jdv.14913","article-title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","volume":"32","author":"Gottlieb","year":"2018","journal-title":"J. Eur. Acad. Derm. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2020.1749546","article-title":"Efficacy of brodalumab in the treatment of scalp and nail psoriasis: Results from three phase 3 trials","volume":"33","author":"Elewski","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/art.20926","article-title":"Recommendations for musculoskeletal ultrasonography by rheumatologists: Setting global standards for best practice by expert consensus","volume":"53","author":"Brown","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S1470-2045(11)70215-7","article-title":"Consensus-based standards for best supportive care in clinical trials in advanced cancer","volume":"13","author":"Zafar","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1378\/chest.09-1543","article-title":"American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease","volume":"137","author":"Mahler","year":"2010","journal-title":"Chest"},{"key":"ref_34","unstructured":"(2022, October 05). SILIQ\u2122 (Brodalumab) Injection, for Subcutaneous Use Initial U.S. Approval: 2017, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf."},{"key":"ref_35","unstructured":"(2022, November 12). Foglio Illustrativo: Informazioni per il Paziente Kyntheum 210 mg Soluzione Iniettabile in Siringa Preriempita Brodalumab, Available online: https:\/\/farmaci.agenziafarmaco.gov.it\/aifa\/servlet\/PdfDownloadServlet?pdfFileName=footer_000819_045484_FI.pdf&sys=m0b1l3."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fresegna, D., Bullitta, S., Musella, A., Rizzo, F.R., De Vito, F., Guadalupi, L., Caioli, S., Balletta, S., Sanna, K., and Dolcetti, E. (2020). Re-Examining the Role of TNF in MS Pathogenesis and Therapy. Cells, 9.","DOI":"10.3390\/cells9102290"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejim.2012.12.015","article-title":"Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases","volume":"24","author":"Sinagra","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","article-title":"Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: Subgroup analysis of a randomized phase III trial (AMAGINE-1)","volume":"183","author":"Papp","year":"2020","journal-title":"Br. J. Derm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"212570","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: Evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs Context"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jdv.16816","article-title":"Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3","volume":"35","author":"Warren","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s13555-021-00618-5","article-title":"Increased Skin Clearance and Quality of Life Improvement with Brodalumab Compared with Ustekinumab in Psoriasis Patients with Aggravating Lifestyle Factors","volume":"11","author":"Kokolakis","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br. J. Derm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100266","DOI":"10.1016\/j.lanepe.2021.100266","article-title":"Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","article-title":"Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial","volume":"82","author":"Puig","year":"2020","journal-title":"J. Am. Acad. Derm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221111111","article-title":"Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies","volume":"26","author":"Yeung","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2147\/DDDT.S113683","article-title":"Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: Design, development, and potential place in therapy","volume":"11","author":"Roman","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","article-title":"Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors","volume":"84","author":"Yeung","year":"2021","journal-title":"J. Am. Acad. Derm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e15106","DOI":"10.1111\/dth.15106","article-title":"Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis","volume":"34","author":"Loft","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Miyagawa, F. (2022). Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071485"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s13555-020-00411-w","article-title":"Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics","volume":"10","author":"Menter","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Carstens, E., and Akiyama, T. (2014). Itch: Mechanisms and Treatment, Frontiers in Neuroscience; CRC Press\/Taylor & Francis.","DOI":"10.1201\/b16573"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CCID.S4465","article-title":"Itch in psoriasis: Epidemiology, clinical aspects and treatment options","volume":"2","author":"Prignano","year":"2009","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14712598.2021.1941862","article-title":"Use of brodalumab for the treatment of chronic plaque psoriasis: A one-year real-life study in the Lazio region, Italy","volume":"21","author":"Galluzzo","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_56","first-page":"46","article-title":"Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry","volume":"237","author":"Mason","year":"2021","journal-title":"DRM"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Nicolescu, A.C., Ionescu, M.-A., Constantin, M.M., Ancuta, I., Ionescu, S., Niculet, E., Tatu, A.L., Zirpel, H., and Tha\u00e7i, D. (2022). Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life, 12.","DOI":"10.3390\/life12122050"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/ijd.IJD_539_16","article-title":"Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis","volume":"62","author":"Sarma","year":"2017","journal-title":"Indian J Derm."},{"key":"ref_59","first-page":"33","article-title":"Management of scalp psoriasis: Current perspectives","volume":"6","author":"Blakely","year":"2016","journal-title":"Psoriasis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/09546634.2020.1770175","article-title":"Psoriasis in difficult to treat areas: Treatment role in improving health-related quality of life and perception of the disease stigma","volume":"33","author":"Lanna","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1590\/abd1806-4841.20142633","article-title":"Nail psoriasis: A review of the literature","volume":"89","author":"Schons","year":"2014","journal-title":"An. Bras. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2014.2983","article-title":"National Psoriasis Foundation Treatment of nail psoriasis: Best practice recommendations from the Medical Board of the National Psoriasis Foundation","volume":"151","author":"Crowley","year":"2015","journal-title":"JAMA Derm."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","article-title":"Prevalence of genital psoriasis in patients with psoriasis","volume":"29","author":"Meeuwis","year":"2018","journal-title":"J. Dermatol. Treat"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaad.2014.10.026","article-title":"Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis","volume":"72","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Derm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s13555-022-00746-6","article-title":"Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis","volume":"12","author":"Menter","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_66","unstructured":"Segaert, S., Andersen, J., and Nielsen, V. (2018, January 12\u221216). Efficacy of Brodalumab, an Interleukin-17 Receptor Antibody, on Clinical Signs of Moderate to Severe Plaque Psoriasis in Different Body Regions. Abstract P0457. Proceedings of the 27th EADV Congress, Paris, France."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"(2017). Improvement of nail psoriasis with brodalumab in phase 3 trials. J. Am. Acad. Dermatol., 76, AB410.","DOI":"10.1016\/j.jaad.2017.06.080"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"146","DOI":"10.36849\/JDD.4969","article-title":"Treatment of Nail Psoriasis","volume":"21","author":"Kassir","year":"2022","journal-title":"J. Drugs Dermatol."},{"key":"ref_69","first-page":"e14351","article-title":"Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases","volume":"33","author":"Megna","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjd.14702","article-title":"Japanese Brodalumab Study Group Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: Results from a 52-week, open-label study","volume":"176","author":"Yamasaki","year":"2017","journal-title":"Br. J. Derm."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e14338","DOI":"10.1111\/dth.14338","article-title":"Recurrent erythrodermic psoriasis and polycythemia successfully treated with brodalumab","volume":"33","author":"Bernardini","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s13555-021-00612-x","article-title":"Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s13555-022-00736-8","article-title":"Symptom Experience and Content Validity of the Psoriasis Symptom Scale (PSS) in Patients with Generalized Pustular Psoriasis (GPP)","volume":"12","author":"Burden","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.25251\/skin.5.supp.50","article-title":"Retreatment With Brodalumab Results in Skin Clearance and Improvements in Quality of Life in Patients with Psoriasis After Treatment Interruption","volume":"5","author":"Armstrong","year":"2021","journal-title":"J. Ski."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bjd.18327","article-title":"Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: Analysis of two randomized controlled trials","volume":"182","author":"Hsu","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000156599","article-title":"Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project","volume":"217","author":"Naldi","year":"2008","journal-title":"Dermatology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.17738","article-title":"Factors predicting persistence of biologic drugs in psoriasis: A systematic review and meta-analysis","volume":"181","author":"Mourad","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5114\/ada.2020.94835","article-title":"The influence of body weight of patients with chronic plaque psoriasis on biological treatment response","volume":"37","author":"Kisielnicka","year":"2020","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"AB163","DOI":"10.1016\/j.jaad.2020.06.740","article-title":"15908 Long-term efficacy and safety of brodalumab in patients with or without metabolic syndrome","volume":"83","author":"Strober","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: Results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3545\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:37:49Z","timestamp":1760125069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":80,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103545"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103545","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]}}}